Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Reporting Period: Single event date (February 23, 2026)
Business Overview: The Company is an emerging growth company incorporated in Texas, focused on proprietary antiviral compounds. It is listed on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Events
The primary material event disclosed under Item 7.01 (Regulation FD Disclosure) is the announcement of new data regarding the Company's proprietary and patented antiviral compound, MGX-0024. Key developments include:
- Field Trials: Results from commercial poultry field trials in India involving approximately 29,000 birds showed zero respiratory-related mortality.
- Challenge Study: A government-conducted challenge study demonstrated prophylactic benefits of the compound against H5N1.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the positive trial results. No specific financial guidance or revenue projections were included in this text.
Risks and Contingencies: The filing includes a standard Forward-Looking Statements disclaimer. It notes that statements regarding future events, expectations, and beliefs are subject to risks and uncertainties that could cause actual results to differ materially. The Company explicitly states it undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the full details of the press release attached as Exhibit 99.1 regarding the MGX-0024 field trials and H5N1 study.
- Confirm the regulatory status and approval pathway for MGX-0024 in India and other target markets.
- Review the Company's most recent Form 10-Q or 10-K for current financial health, cash runway, and debt obligations, as this 8-K contains no financial data.
- Assess the commercial scalability of the poultry field trial results to broader markets.